Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The potential of targeting epigenetic regulators for the treatment of fibrotic cardiac diseases.

Literature DB >> 27556930

The potential of targeting epigenetic regulators for the treatment of fibrotic cardiac diseases.

Katherine B Schuetze¹, Keith A Koch¹, Timothy A McKinsey¹.

Abstract

Entities: Disease

Keywords: epigenetics; fibrosis; heart; small molecules

Mesh：

Substances：

Year: 2016 PMID： 27556930 PMCID： PMC5558550 DOI： 10.4155/fmc-2016-0144

Source DB: PubMed Journal: Future Med Chem ISSN： 1756-8919 Impact factor: 3.808

Keyword Cloud
References

× No keyword cloud information.

18 in total

Review 1. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.

Authors: Erik W Bush; Timothy A McKinsey
Journal: Circ Res Date: 2010-02-05 Impact factor: 17.367

2. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin.

Authors: Begoña López; Arantxa González; Ramón Querejeta; Elena Zubillaga; Mariano Larman; Javier Díez
Journal: Eur J Heart Fail Date: 2015-02-11 Impact factor: 15.534

3. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).

Authors: Omar F AbouEzzeddine; Phillip Haines; Susanna Stevens; Jose Nativi-Nicolau; G Michael Felker; Barry A Borlaug; Horng H Chen; Russell P Tracy; Eugene Braunwald; Margaret M Redfield
Journal: JACC Heart Fail Date: 2015-03 Impact factor: 12.035

Review 4. Epigenetic regulation of cardiac fibrosis.

Authors: Matthew S Stratton; Timothy A McKinsey
Journal: J Mol Cell Cardiol Date: 2016-02-12 Impact factor: 5.000

5. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.

Authors: Sandy Amorim; Anastasios Stathis; Mary Gleeson; Sunil Iyengar; Valeria Magarotto; Xavier Leleu; Franck Morschhauser; Lionel Karlin; Florence Broussais; Keyvan Rezai; Patrice Herait; Carmen Kahatt; François Lokiec; Gilles Salles; Thierry Facon; Antonio Palumbo; David Cunningham; Emanuele Zucca; Catherine Thieblemont
Journal: Lancet Haematol Date: 2016-03-18 Impact factor: 18.959

10. HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation.

Authors: Hikmet F Nural-Guvener; Luidmila Zakharova; James Nimlos; Snjezana Popovic; Diego Mastroeni; Mohamed A Gaballa
Journal: Fibrogenesis Tissue Repair Date: 2014-07-02

The potential of targeting epigenetic regulators for the treatment of fibrotic cardiac diseases.

Review 1. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.

2. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin.

3. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).

Review 4. Epigenetic regulation of cardiac fibrosis.

5. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.

6. Are chargemaster rates for imaging studies lower in States that cap noneconomic damages (tort reform)?

7. Revisiting Cardiac Cellular Composition.

8. BET acetyl-lysine binding proteins control pathological cardiac hypertrophy.

9. Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes.

10. HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation.